Patents Represented by Attorney, Agent or Law Firm Steven P. Caltrider
-
Patent number: 5650486Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.Type: GrantFiled: June 1, 1995Date of Patent: July 22, 1997Assignee: Eli Lilly and CompanyInventor: Michael R. De Felippis
-
Patent number: 5646242Abstract: The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free .epsilon.-amino group of insulin, insulin analog, or proinsulin in the presence of a free .alpha.-amino group.Type: GrantFiled: November 17, 1994Date of Patent: July 8, 1997Assignee: Eli Lilly and CompanyInventors: Jeffrey C. Baker, Victor J. Chen, Jose M. Hanquier, Aidas Kriauciunas, Brian A. Moser, Robert T. Shuman
-
Patent number: 5631347Abstract: A method for processing a fatty acid-acylated protein, especially N-palmitoyl Lys.sup.B29 human insulin, to reduce the incidence of gelation by conducting such processing in the presence of a citrate buffering agent as the primary buffer which method allows such processing to be conducted at higher protein concentrations and with less temperature control than would otherwise be possible in the absence of the citrate buffer.Type: GrantFiled: June 7, 1995Date of Patent: May 20, 1997Assignee: Eli Lilly and CompanyInventors: Jeffrey C. Baker, Jose M. Hanquier, Warren E. Shrader
-
Patent number: 5624949Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.Type: GrantFiled: March 30, 1995Date of Patent: April 29, 1997Assignee: Eli Lilly and CompanyInventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
-
Patent number: 5624953Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.Type: GrantFiled: February 2, 1996Date of Patent: April 29, 1997Assignee: Eli Lilly and CompanyInventors: Samantha J. Ambler, William F. Heath, Jr., Jai Pal Singh, Colin W. Smith, Lawrence E. Stramm
-
Patent number: 5621098Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R.sub.1, R.sub.2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.Type: GrantFiled: June 1, 1995Date of Patent: April 15, 1997Assignee: Eli Lilly and CompanyInventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
-
Patent number: 5614379Abstract: The present invention is directed to a novel process of preparing an anti-obesity protein using dipeptidyl-aminopeptidase isolated from the cellular slime mold, Dictyostelium discodeum. The process produces an anti-obesity protein in high yield.Type: GrantFiled: April 26, 1995Date of Patent: March 25, 1997Assignee: Eli Lilly and CompanyInventor: Warren C. MacKellar
-
Patent number: 5614647Abstract: The present invention provides a novel synthesis of the compounds of Formula (I): ##STR1## The compounds are produced in high yield and without utilizing expensive chromatographic separations. The synthesis is particularly advantageous because it is stereoselective.Type: GrantFiled: May 25, 1995Date of Patent: March 25, 1997Assignee: Eli Lilly and CompanyInventors: Margaret M. Faul, Michael R. Jirousek, Leonard L. Winneroski, II
-
Patent number: 5612360Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.Type: GrantFiled: April 20, 1993Date of Patent: March 18, 1997Assignee: Eli Lilly and CompanyInventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
-
Patent number: 5605886Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: May 17, 1995Date of Patent: February 25, 1997Assignee: Eli Lilly and CompanyInventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
-
Patent number: 5594104Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: February 6, 1995Date of Patent: January 14, 1997Assignee: Eli Lilly and CompanyInventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
-
Patent number: 5594101Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: March 3, 1995Date of Patent: January 14, 1997Assignee: Eli Lilly and CompanyInventors: Gerald W. Becker, John E. Hale, Warren C. MacKellar
-
Patent number: 5580900Abstract: A compound of the formula: ##STR1## in which each R.sup.1 to R.sup.4 group is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkoxy-carbonyl, halo, hydroxy, nitro, cyano, trihalomethyl or optionally substituted phenyl, each R.sup.5 to R.sup.16 group is hydrogen or C.sub.1-4 alkyl, each Z', Z", Z'" and Z"" group is an alkylene radical, and X and Y are each --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.m --A--(CH.sub.2).sub.p -- where A is --CH.dbd.CH--, optionally substituted phenylene or optionally substituted naphthalenyl, n is 2 to 10, and m and p are each 1 or 2, salts thereof, and intermediates for the production thereof.Type: GrantFiled: November 30, 1994Date of Patent: December 3, 1996Assignee: Lilly Industries LimitedInventors: Barry P. Clark, John R. Harris
-
Patent number: 5580954Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: January 31, 1995Date of Patent: December 3, 1996Assignee: Eli Lilly and CompanyInventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
-
Patent number: 5574133Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: January 31, 1995Date of Patent: November 12, 1996Assignee: Eli Lilly and CompanyInventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
-
Patent number: 5571925Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.Type: GrantFiled: January 19, 1994Date of Patent: November 5, 1996Assignee: Eli Lilly and CompanyInventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
-
Patent number: 5569743Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: January 31, 1995Date of Patent: October 29, 1996Assignee: Eli Lilly and CompanyInventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffman, James E. Shields, David L. Smiley
-
Patent number: 5569744Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: February 6, 1995Date of Patent: October 29, 1996Assignee: Eli Lilly and CompanyInventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
-
Patent number: 5567803Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: February 6, 1995Date of Patent: October 22, 1996Assignee: Eli Lilly and CompanyInventors: Margret Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
-
Patent number: 5567678Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.Type: GrantFiled: January 31, 1995Date of Patent: October 22, 1996Assignee: Eli Lilly and CompanyInventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley